Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
| ▸ | HTR3B | O95264 | 1/20 | 0.72 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.72 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.72 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.72 |
| ▸ | HTR3A | P46098 | 1/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.72 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.72 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324147 | 0.92 | CYP3A4 (0.62) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL13324143 | 0.92 | CYP3A4 (0.65) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL13324145 | 0.87 | CYP3A4 (0.58) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL2615456 | 0.87 | CYP3A4 (0.56) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL2615454 | 0.87 | CYP3A4 (0.56) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9596706 | 0.84 | CYP3A4 (0.68) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL848379 | 0.84 | CYP3A4 (1.00) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL1560211 | 0.84 | CYP3A4 (1.00) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29358872 | 0.84 | CYP3A4 (1.00) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL4542 | 0.84 | CYP3A4 (1.00) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170105970-A1 | ONDANSETRON SUBLINGUAL SPRAY FORMULATION | BENUVIA OPERATIONS, LLC | 2017-04-20 | — | — | US | disclosed |
| US-20170042861-A1 | Sublingual Ondansetron Spray | BENUVIA OPERATIONS, LLC | 2017-02-16 | — | — | US | disclosed |
| US-9566233-B2 | Ondansetron sublingual spray formulation | INSYS DEVELOPMENT COMPANY, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GLOBAVIR BIOSCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20150133517-A1 | ONDANSETRON SUBLINGUAL SPRAY FORMULATION | BENUVIA OPERATIONS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-20120202866-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | SUDA LTD. (AU) | 2012-08-09 | — | — | US | disclosed |
| US-20110160264-A1 | ORALLY ADMINISTRABLE FILM DOSAGE FORMS CONTAINING ONDANSETRON | MONOSOL RX, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100152262-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | DUGGER III HARRY A | 2010-06-17 | — | — | US | disclosed |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090162297-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | DUGGER III HARRY A | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042861-A1 | Sublingual Ondansetron Spray | SLC6A4, SLC6A2, SLC6A3 | CYP3A4 107/4885KCNH2 1828/4885CYP1A2 313/4885 |
| US-20170105970-A1 | ONDANSETRON SUBLINGUAL SPRAY FORMULATION | SLC6A4, SLC6A5, SLC6A3 | CYP3A4 68/4885KCNH2 1277/4885CYP1A2 328/4885 |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | CYP3A4 4879/4885KCNH2 3344/4885CYP1A2 4843/4885 |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | SLC6A3, SLC6A4, ADH5 | CYP3A4 85/4885KCNH2 945/4885CYP1A2 148/4885 |
| US-20090162297-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | TAS2R5, TAS2R4, MC2R | CYP3A4 58/4885KCNH2 701/4885CYP1A2 489/4885 |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | SLC6A3, SLC6A4, SLC6A2 | CYP3A4 619/4885KCNH2 2086/4885CYP1A2 468/4885 |
| US-20120202866-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | TAS2R5, TAS2R4, MC2R | CYP3A4 58/4885KCNH2 701/4885CYP1A2 489/4885 |
| US-20100152262-A1 | BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ONDANSETRON | TAS2R5, TAS2R4, MC2R | CYP3A4 58/4885KCNH2 701/4885CYP1A2 489/4885 |
| US-20110160264-A1 | ORALLY ADMINISTRABLE FILM DOSAGE FORMS CONTAINING ONDANSETRON | CYP3A5, CYP3A7, SLC6A4 | CYP3A4 11/4885KCNH2 1236/4885CYP1A2 45/4885 |
| US-20150133517-A1 | ONDANSETRON SUBLINGUAL SPRAY FORMULATION | SLC6A4, SLC6A5, SLC6A3 | CYP3A4 68/4885KCNH2 1277/4885CYP1A2 328/4885 |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | IDO2, IDO1, TDO2 | CYP3A4 3365/4885KCNH2 4769/4885CYP1A2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.